Bevacizumab, a VEGF inhibitor (a recombinant humanized monoclonal antibody against VEGF), has been used in clinical trials for the treatment of head and neck cancer (HNC), where it has significantly improved radiation therapy (Ahn et al., 2018). This evidence concerns the gene VEGFA and head and neck cancer.